Roche: to present new data at breast cancer congress
(CercleFinance.com) - Roche is working towards presenting new and updated data for seven approved and investigational drugs at the San Antonio Breast Cancer Symposium next month, the Swiss drugmaker said on Monday.
New data will be presented from a second interim overall survival (OS) analysis of a phase III trial evaluating Perjeta and Herceptin plus chemotherapy compared to Herceptin and chemotherapy as an adjuvant treatment for HER2-positive early breast cancer, it said.
The Basel-based company also plans to unveil results from a phase III study confirming the non-inferiority of a fixed-dose combination of Perjeta and Herceptin administered under the skin.
Roche will also present study results reflecting advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer, the group said.
The San Antonio Breast Cancer Symposium will be held from 10 to 14 December.
Copyright (c) 2019 CercleFinance.com. All rights reserved.